Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · Real-Time Price · USD
7.66
+0.21 (2.82%)
Aug 19, 2026, 4:00 PM EDT - Market closed
Shattuck Labs Revenue
Shattuck Labs had revenue of $1.00M in the twelve months ending June 30, 2026. In the year 2025, Shattuck Labs had annual revenue of $1.00M, down -82.52%.
Revenue (ttm)
$1.00M
Revenue Growth
-82.52%
P/S Ratio
768.78
Revenue / Employee
$25,000
Employees
40
Market Cap
768.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.00M | -4.72M | -82.52% |
| Dec 31, 2024 | 5.72M | 4.06M | 245.26% |
| Dec 31, 2023 | 1.66M | 1.01M | 154.14% |
| Dec 31, 2022 | 652.00K | -29.37M | -97.83% |
| Dec 31, 2021 | 30.02M | 20.08M | 202.16% |
| Dec 31, 2020 | 9.93M | 47.00K | 0.48% |
| Dec 31, 2019 | 9.89M | -12.56M | -55.94% |
| Dec 31, 2018 | 22.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 239.66M |
| REGENXBIO | 174.48M |
| Gyre Therapeutics | 109.82M |
| 4D Molecular Therapeutics | 92.01M |
| CytomX Therapeutics | 18.30M |
| Crescent Biopharma | 11.88M |
| Allogene Therapeutics | 4.64M |
| Neurogene | 925.00K |
STTK News
- 8 days ago - Shattuck Labs price target lowered to $14 from $18 at H.C. Wainwright - TheFly
- 8 days ago - Shattuck Labs Quarterly report: Q2 2026 - Filings
- 8 days ago - Shattuck Labs Earnings release: Q2 2026 - Filings
- 8 days ago - Shattuck Labs Slides: Corporate presentation - Filings
- 8 days ago - Shattuck Labs reports Q2 EPS (12c), consensus (12c) - TheFly
- 26 days ago - Shattuck Labs initiated with an Overweight at JPMorgan - TheFly
- 4 weeks ago - Shattuck Labs initiated with an Outperform at Leerink - TheFly
- 4 weeks ago - Shattuck Labs initiated with an Outperform at Leerink - TheFly